Saturday, March 19, 2011
Medical News: SGO: Mutation Link to Ovarian Cancer Disputed - in Meeting Coverage, SGO from MedPage (KRAS mutation)
Blogger's note: odd that the story didn't mention how the patient is doing ??
"....The panel heard that at a later consultation, the progress of the condition was again not identified and acted on, with poor notes made.
A specialist was not consulted and clinical standards of care were not met...."
abstract: Informed consent to microsatellite instability and immunohistochemistry screening for Lynch syndrome (ethics/informed consent)
From the 1Department of Bioethics, Cleveland Clinic; 2Genomic Medicine Institute Lerner College of Medicine, Cleveland Clinic; and 3Center for Genomic Research Ethics & Law, Case Western Reserve University, Cleveland, Ohio.
AbstractOBJECTIVE: Routine microsatellite instability (MSI) and immunohistochemistry (IHC) screening of colorectal cancers can assist in identifying a significant proportion of cancers attributable to Lynch syndrome. This article considers whether it is necessary to obtain patient informed consent for microsatellite instability and immunohistochemistry screening.
RESULTS: Although microsatellite instability screening examines genetic features of a tumor, it lacks several important characteristics that typically mandate formal informed consent to genetic testing. Microsatellite instability screening describes discrete tissue samples and does not provide information about the rest of the patient's body or germline. In contrast, immunohistochemistry screening is a proteomic test that may reveal information about the patient's germline. As such, immunohistochemistry screening can be viewed as similar to other forms of genetic testing, in which explicit patient consent is regarded as an ethical prerequisite.
CONCLUSION: There is no ethical requirement to obtain explicit informed consent for microsatellite instability screening of colorectal tumor samples for Lynch syndrome. There is support for obtaining patient consent to immunohistochemistry testing, given its similarities with other genetic analyses for which informed consent is typically deemed necessary. Regardless of which screening test is used, it is important to prepare patients and their families for the possibility of a positive screening test.
Mar 15th, 2011 - free full access - A National Registry for Healthy Volunteers in Phase 1 Clinical Trials - — JAMA
Friday, March 18, 2011
Note: full free access/requires registration
"Short- and Long-Term Effects of Surgical MenopauseSecond, the performance of a bilateral oophorectomy in a premenopausal woman, so-called "surgical menopause," can result in very distressing menopausal symptoms, such as hot flashes, depression, sleep disturbances, vaginal dryness, painful intercourse, etc. It is important to acknowledge that these symptoms are often described as being substantially worse than those experienced following natural menopause. The impact of these symptoms on an individual woman's overall quality-of-life should not be underestimated.
Again, the point of noting this concern is not to deny the utility of this surgery in women with a substantial risk of developing ovarian cancer. Rather, it is to be certain that this issue is discussed with the individual woman prior to the performance of the procedure. In this way, she can include this information in her decision-making process....."
Saturday, March 19 · 12:00pm - 2:00pm
OCATS AGM with Judy Wright, Guest Speaker
Knox Met United Church, Room 105
2340 Victoria Avenue
Election of Board Members
Presentation of financial Statement for 2010
Vote on Change to Bylaws/ARticles/Constituti
Guest Speaker: Gifted Counsellor Judy Wright, Judy will share with us a new endeavor of hers, working with clients and horses to help people overcome barriers and physical and emotional pain.
Light Lunch by Donation
Memberships can be renewed at the door.
If you are a paid member, you can vote by proxy, email firstname.lastname@example.org
Thursday, March 17, 2011
Drug company (Mylan Pharmaceuticals) recalls pills over dangerous labelling mix-up (Mylan-Minocycline/ Mylan-Amlodipine)
"A pharmaceutical company has launched a voluntary recall of a drug which may have been mislabelled — with possible "life-threatening" consequences for patients with high blood pressure, says Health Canada.
Following a complaint by a pharmacist regarding a prescription product containing the wrong medication, Mylan Pharmaceuticals is recalling one lot of Mylan-Minocycline 50 mg capsules and Mylan-Amlodipine 5 mg tablets, both sold in bottles of 100.
The risk, says Health Canada, is that patients sensitive to tetracyclines or minocycline may be taking minocycline in error, due to mislabelled bottles.
"In addition, a patient who requires MYLAN-AMLODIPINE for their high blood pressure or angina will not get the medication needed to help them treat these conditions," said a Health Canada statement.
Mylan-Amlodipine is used to treat high blood pressure and chest pains. Mylan-Minocycline is used to treat certain types of skin infections, urinary tract infections, gallbladder infections, and respiratory tract infections such as bronchitis, pneumonia, and sinusitis.
WHO warns against self-medicating against radiation
17 March 2011 -- WHO is cautioning people concerned about the radiation issues in Japan against self-medicating with potassium iodide or taking products containing iodine. The advice follows reports of people using these substances in response to radiation leaks from nuclear plants in Japan. Potassium iodide should only be taken when there is a clear public health recommendation to do so.
full free access: PLoS ONE: Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis (Mar 15/2011)
Note: research/technical/primary focus on serous cell type
Objective10% of women with serous ovarian cancer have low-grade carcinomas. These patients are diagnosed at a younger age, have a longer overall survival and a lower response rate to platinum-based chemotherapy compared to women with high-grade serous ovarian carcinoma. It remains unclear if these features are similar in women with low-grade primary peritoneal cancer (PPC). To further explore this issue, a retrospective analysis of the clinical and pathologic characteristics of women with low-grade serous PPC was performed.
ConclusionTo our knowledge, this is the first report of women with low-grade serous PPC. Similar to low-grade serous ovarian carcinoma, patients with low-grade serous PPC have high rates of persistent disease at the completion of primary treatment yet a long overall survival. Further study focusing specifically on low-grade serous ovarian and primary peritoneal carcinomas is needed to determine the optimal treatment of these diseases.
Research Highlights► This study is the first reported series of women with low-grade serous primary peritoneal cancer.
► The pathogenesis and clinical behavior of low-grade serous ovarian and primary peritoneal are distinct from high-grade serous tumors.
► Women with low-grade primary peritoneal cancer have high rates of persistent disease at the completion of primary treatment, yet have a prolonged survival.
add your opinions Primary peritoneal cancer; Low-grade serous carcinoma; Ovarian cancer
Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?
ObjectiveTo compare survival of ovarian cancer patients treated with neoadjuvant chemotherapy followed by intraperitoneal (IP) versus intravenous (IV) chemotherapy after optimal interval debulking.
ConclusionsSurvival benefit associated with IP chemotherapy after optimal upfront surgery may not translate to the neoadjuvant setting.
Radical fimbriectomy: A reasonable temporary risk-reducing surgery for selected women with a germ line mutation of 1 or 2 genes? Rationale and preliminary development
Research Highlights►Radical fimbriectomy is a new kind of temporary prophylactic operation in BRCA mutation carriers. ►It removes both fallopian tubes including the frimbrio-ovarian junctions. ►It reduces the risk of high-grade pelvic serous cancer while preserving ovarian function.
|articles 1 - 43|